Renovacor Announces the Appointments of Joan Lau, Ph.D., and Gregory F. Covino to its Board of Directors

Appointments to be productive on closing of the beforehand announced merger concerning Renovacor and Chardan Healthcare Acquisition 2 Corp.

PHILADELPHIA, June 29, 2021 (World NEWSWIRE) — Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company acquiring adeno-involved virus (AAV)‑based gene therapies for devastating cardiovascular and central anxious process diseases ensuing from BAG3 gene variants, currently announced the appointments of Joan Lau, Ph.D., and Gregory F. Covino to its Board of Administrators, powerful upon the closing of the earlier declared merger (the “Merger”) amongst Renovacor and Chardan Health care Acquisition 2 Corp. (NYSE: CHAQ) (“CHAQ”). The closing of the Merger is predicted to arise in the 3rd quarter of 2021. On the close of the Merger, Mr. Covino will also serve as the Chair of Renovacor’s Audit Committee.

“Joan and Greg are attained field leaders with proven track records and we are thrilled to welcome them to our Board,” mentioned Magdalene Prepare dinner, M.D., main government officer of Renovacor. “Joan’s intensive management expertise in gene therapy and the broader biotech area, together with Greg’s prosperity of know-how in finance, accounting and money markets, will be invaluable as we get started functioning as a publicly traded organization. We glimpse forward to benefiting from their strategic steerage as we operate to advance REN-001 to the clinic and execute on our company targets.”

Dr. Lau commented, “It is an honor to be signing up for Renovacor’s Board. The business has amazing preclinical datasets and a sound improvement system, as it is utilizing a validated capsid to handle a monogenic sickness with a regarded origin. I look ahead to doing the job with my fellow administrators and Renovacor’s world class scientific advisors to give worthwhile insights and counsel to the company’s administration group.”

Mr. Covino extra, “The opportunity to be part of Renovacor’s board is definitely enjoyable. The enterprise is operating to address a urgent unmet require with a exceptional therapeutic strategy. It is also poised to enter the community market place with a strong financial foundation and the backing of a premier team of institutional investors, which leaves it properly positioned for sustained achievements.”

Tale continues

Dr. Lau brings around 20 several years of biopharma management, drug advancement, and undertaking investing and transaction experience to Renovacor’s Board. She is at this time the chief government officer (CEO) of Spirovant Sciences, a gene treatment enterprise concentrated on altering the training course of cystic fibrosis and other respiratory illnesses. Dr. Lau co-launched Spirovant (then called Talee Bio), and under Dr. Lau’s leadership, Spirovant received the prestigious scientific guidance of the Cystic Fibrosis Basis, obtained the Philadelphia Alliance for Funds and Technologies’ Health care startup of the yr award and was acquired twice, initial by Roivant Sciences, and most just lately as aspect of a $3 billion transaction with Sumitomo Dainippon Pharma, which organized Spirovant as a wholly-owned subsidiary of Sumitovant Biopharma Ltd. Ahead of co-founding Spirovant, Dr. Lau co-founded and served as running spouse of Militia Hill Ventures. In addition, she led several other businesses, serving as CEO of Azelon Prescribed drugs, president and CEO of Locus Prescribed drugs, main running officer of Immunome and in numerous leadership roles at Merck, together with in R&D drug growth and business enterprise improvement features. Dr. Lau’s function in the biopharma market has gained her several honors, such as becoming regarded as a winner of the 2020 Ernst & Youthful Entrepreneur of the Yr Award in Better Philadelphia and as a 2020 Lady of Difference by the Philadelphia Small business Journal. Dr. Lau has a Ph.D. in neuroscience from the College of Cincinnati University of Medication, an MBA from the Wharton College of Company at the University of Pennsylvania and a BSE in Bioengineering from the University of Pennsylvania.

Mr. Covino is a deeply knowledgeable economical government with extensive leadership, operations, approach and accounting skills. He is now an government advisor at Novavax, Inc., where by he also served as main economical officer (CFO) and led the completion of a $500 million at-the-marketplace money raise. Prior to signing up for Novavax, Mr. Covino worked as senior vice president and main accounting officer of TESARO, Inc. by means of the company’s $5.1 billion acquisition by GlaxoSmithKline (GSK). Adhering to this acquisition, GSK retained Mr. Covino as group CFO of its newly fashioned TESARO Oncology Division. Mr. Covino also formerly labored for more than 6 yrs as the main accounting officer of Biogen Inc., wherever he was liable for accounting, business enterprise evaluation, interior handle and money reporting features. During his time at Biogen, Mr. Covino assisted guide the finance functionality by a period of time of swift growth subsequent the professional achievements of the company’s new goods and in depth alliances. Earlier to Biogen, Mr. Covino held positions as main internal audit govt, and vice president, worldwide finance for Boston Scientific. On top of that, Mr. Covino invested 10 years at the global accounting and consulting firm PricewaterhouseCoopers, where he gained substantial encounter associated to accounting, fiscal reporting, finance operations, inner controls, M&A and company taxation. Mr. Covino earned his bachelor’s diploma in organization administration from Bryant University, in which he has also served as an adjunct professor.

About Renovacor
Renovacor is a preclinical phase gene treatment enterprise acquiring a pipeline of impressive and proprietary AAV-based gene therapies for BAG3 gene mutation-linked health conditions in places of superior unmet medical want. Renovacor’s therapeutic target is in the beginning on cardiovascular sickness, with a guide program in BAG3 mutation-involved dilated cardiomyopathy. For much more facts, remember to go to www.renovacor.com. No element of Renovacor’s website is included by reference into or otherwise considered to be a section of this press release.

Renovacor formerly announced that it experienced entered into a merger settlement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) (“CHAQ”), a distinctive reasons acquisition enterprise. Completion of the proposed merger is subject to approval by the shareholders of CHAQ and sure other situations. The merger is expected to shut in the third quarter of 2021.

About Chardan Health care Acquisition Corp.
CHAQ is a special intent acquisition company fashioned for the goal of effecting a merger, acquisition, or equivalent business enterprise blend. CHAQ lifted around $86. million in April 2020 for the goal of combining with a general public or privately-held functioning enterprise. CHAQ was launched and sponsored by affiliate marketers of Chardan Cash Markets LLC. CHAQ is Chardan’s sixth publicly traded acquisition auto.

Further Information and facts and Where by to Uncover It
This communication is becoming built in regard of a proposed transaction in between Renovacor and CHAQ. This document does not constitute an supply to offer or exchange, or the solicitation of an give to invest in or trade, any securities, nor shall there be any sale of securities in any jurisdiction in which this kind of provide, sale or trade would be illegal prior to registration or qualification underneath the securities legislation of any this sort of jurisdiction. CHAQ intends to file a proxy assertion, which will be despatched to all CHAQ and Renovacor stockholders. CHAQ also will file other documents concerning the proposed transaction with the Securities and Trade Fee (the “SEC”). Right before Generating ANY VOTING Final decision, Traders AND Security HOLDERS OF CHAQ AND RENOVACOR ARE URGED TO Browse THE PROXY Statement, AS Could BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ALL OTHER Suitable Files Submitted OR THAT WILL BE Filed WITH THE SEC IN Connection WITH THE PROPOSED TRANSACTION AS THEY Turn into Obtainable Since THEY WILL Consist of Vital Facts ABOUT THE PROPOSED TRANSACTION AND THE Events THERETO.

Buyers and safety holders will be in a position to obtain cost-free copies of the proxy statement and all other pertinent files submitted or that will be filed with the SEC by CHAQ through the web-site preserved by the SEC at www.sec.gov. In addition, the paperwork submitted by CHAQ could be received totally free of cost from CHAQ’s site at https://www.chardanhealthcarespac.com/ or by penned ask for to CHAQ at Chardan Healthcare Acquisition 2 Corp., 17 Condition Avenue, 21st Flooring, New York, NY 10004.

Members in Solicitation
CHAQ and Renovacor and their respective administrators and officers may possibly be considered to be participants in the solicitation of proxies from CHAQ’s stockholders in relationship with the proposed transaction. Data about CHAQ’s administrators and govt officers and their ownership of CHAQ’s securities is established forth in CHAQ’s filings with the SEC, including CHAQ’s Once-a-year Report on Variety 10-K for the fiscal 12 months finished December 31, 2020, which was submitted with the SEC on March 4, 2021. To the extent that holdings of CHAQ’s securities have modified because the amounts printed in CHAQ’s Once-a-year Report on Variety 10-K for the fiscal 12 months finished December 31, 2020, which was submitted with the SEC on March 4, 2021, these changes have been or will be reflected on Statements of Improve in Possession on Kind 4 filed with the SEC. Further info regarding the pursuits of all those folks and other persons who may be considered individuals in the proposed transaction might be received by reading through the proxy statement regarding the proposed transaction when it will become accessible. You might receive free copies of these documents as explained in the higher than paragraph.

Ahead-Looking Statements Legend
This communication is made up of particular forward-seeking statements within just the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, as amended, which includes statements relating to the expected timing of the transaction and Renovacor’s products and solutions below development. These ahead-seeking statements normally are recognized by the terms “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will carry on,” “will most likely end result,” and similar expressions. Forward-wanting statements are predictions, projections and other statements about long term functions that are based on current anticipations and assumptions and, as a final result, are subject to dangers and uncertainties. Many things could cause real long run occasions to differ materially from the ahead-looking statements in this communication. You should really very carefully take into account the dangers and uncertainties described in the “Risk Factors” section of CHAQ’s Yearly Studies on Sort 10-K, Quarterly Stories on Variety 10-Q and proxy statement mentioned above and other paperwork submitted by CHAQ from time to time with the SEC. These filings recognize and handle significant threats and uncertainties that could cause actual functions and benefits to vary materially from people contained in the forward-wanting statements. Ahead-hunting statements converse only as of the date they are manufactured. Audience are cautioned not to place undue reliance on forward-hunting statements, and Renovacor and CHAQ presume no obligation and do not intend to update or revise these forward-seeking statements, regardless of whether as a consequence of new information, long run occasions, or in any other case. Neither Renovacor nor CHAQ gives any assurance that either Renovacor or CHAQ will accomplish its expectations.

Trader Call:
John Mullaly
LifeSci Advisors
617-429-3548
[email protected]

Media Speak to:
Patrick Bursey
LifeSci Communications
646-970-4688
[email protected]